European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: PR Newswire
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patientsCardioMEMS is a paperclip-sized sensor that can remotely flag to a patient's clinical team the early warning signs of worsening heart failureABBOTT PARK, Ill., May 24, 2023 /PRNewswire/ -- New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy (GDMT). GDMT refers to the European and U.S. guidelines for heart failure management2 that uses a combination of up to four heart medications. MONITOR-HF is the third randomized, contr
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Drug Device Combination Products Market Worth Over $180 Billion by 2029 - Medtronic, Abbott Laboratories, and Boston Scientific Corporation Dominate the Industry [Yahoo! Finance]Yahoo! Finance
- R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO [Yahoo! Finance]Yahoo! Finance
- Pharmacogenomics Market Worth $19.5 billion by 2031 -- Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- Drugmaker Abbott India posts Q4 profit rise on higher sales [Yahoo! Finance]Yahoo! Finance
- Drugmaker Abbott India posts Q4 profit rise on higher sales [Reuters]Reuters
ABT
Earnings
- 4/17/24 - Beat
ABT
Sec Filings
- 5/10/24 - Form 144
- 5/8/24 - Form 4
- 5/7/24 - Form 144
- ABT's page on the SEC website